Floatz logo

Goserelin

Male Breast Carcinoma

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanoprotein_peptidePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Male Breast Carcinoma cohort.

Asset / SponsorPhaseRating
DOXORUBICIN
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
University of California, Irvine
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

Goserelin is also rated in:

breast cancerActive
BB
Indicative · Phase 4
70 / 100
View asset →
prostate carcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →
prostate adenocarcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →